20 results
P
ovarian cancer patients
I/C
miR-200c, miR-200a, miR-200b, miR-205, miR-145, miR-141, miR-429, and miR-125b, carbohydrate antigen 125
O
diagnostic value
P
women with gestational diabetes mellitus (GDM)
I/C
microRNA (miRNA) as a potential biomarker, normoglycemic controls
O
upregulation of miR-29a, miR-330, miR-134, miR-16, miR-223, and miR-17; decreased levels of miR-132 and miR-155
P
circulating miR-1, miR-133, miR-208, miR-499
I/C
O
diagnostic values in AMI
P
type 2 diabetes mellitus patients with acute ischemic cerebrovascular disease
I/C
circulating microRNA expression profile, control group (T2DM group)
O
upregulation of miR-200a, miR-144, and miR-503, downregulation of miR-126
P
HCC
I/C
miR-497, lower level of miR-497 expression
O
shorter overall survival
P
patients with acute myocardial infarction (AMI), healthy controls, symptomatic controls
I/C
Mir-133a analysis, healthy vs. symptomatic controls
O
diagnostic performance, area under the summary receiver operator characteristic curve (AUC)
P
HCC patients who underwent surgical resection
I/C
miR-21 expression analysis, adjacent nontumor tissues
O
overall survival (OS) and disease-free survival (DFS)
P
ACS patients
I/C
clopidogrel, low plasma miR-223 levels
O
clopidogrel resistance
P
17,746 cases, 21,808 controls
I/C
miR-26a-1 rs7372209 polymorphism, miR-423 rs6505162 polymorphism, homozygote comparison, recessive model, CA versus CC, AA + CA versus CC, AA versus CA + CC, A versus C
O
susceptibility to overall cancer
P
HCC patients, healthy controls, HBV or HCV infection, liver cirrhosis or dysplastic nodule formation
I/C
circulating miR-122, pathophysiological examination
O
diagnostic accuracy